Promethera’s mission is using its proprietary liver cell-based technologies to bringing therapeutic solutions for patients with acute and chronic liver diseases.
Promethera’s technology portfolio consists of versatile and distinct cell therapy technologies, providing unprecedented cell-based platforms to work along three therapeutic pillars: immunomodulation, enzyme/missing factor replacement and cell/tissue regeneration. Promethera’s current focus is primarily on exploiting the immunomodulatory capabilities, which has the potential to deliver truly differentiated therapeutic programs in large indications.
The company’s lead clinical program is derived from a patented allogenic liver cell platform called HepaStem. Currently in a Phase II clinical trial to treat patients with Acute-on-Chronic-Liver Failure (ACLF), the program has the potential to target more prevalent chronic or progressive severe liver diseases such as Non-Alcoholic Steatohepatitis (NASH) and Fibrosis.
PROMETHERA, Hepastem, HepaScreen, H2stem, H3Screen, Cytonet, Heparesc and Hepabridge are registered trademarks or trademarks of PROMETHERA in the Benelux, the United States and other countries.